Form 4: Crinetics Pharmaceuticals Director Caren Deardorf Receives Significant Equity Grants

Crinetics Pharmaceuticals, Inc. Director Caren Deardorf was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation, increasing her beneficial ownership.

Summary

• Caren Deardorf, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), reported the acquisition of equity securities.
• On June 11, 2025, Ms. Deardorf acquired 6,900 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date (June 11, 2026) or the next annual meeting of the Issuer's stockholders, contingent on her continued service on the board.
• Following this transaction, Ms. Deardorf beneficially owns 16,300 shares of Common Stock.
• Additionally, on June 11, 2025, Ms. Deardorf acquired 10,350 stock options (right to buy) with an exercise price of $32.33 per share.
• These stock options will vest and become exercisable on the earlier of the first anniversary of the grant date (June 11, 2026) or the next annual meeting of the Issuer's stockholders, also subject to her continued board service.
• The stock options have an expiration date of June 11, 2035.
• Following this transaction, Ms. Deardorf beneficially owns 10,350 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event, but the director's increased equity stake can be seen as a positive signal of alignment with shareholder interests. There are no negative implications from the filing itself.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of shareholders, as the value of these grants is tied to the company's stock performance.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Negatives

• No inherent negatives are directly indicated by this standard compensation filing.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transactions.

Industry Context

This Form 4 filing reflects a routine compensation event for a director in the biotechnology or pharmaceutical industry, where equity grants are a common component of executive and board member remuneration to incentivize long-term performance and alignment with shareholder interests. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The grant of equity to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: This filing does not directly impact general employees, but it reflects the company's compensation practices for its leadership.

Next Steps

• The restricted stock units and stock options will vest based on the specified conditions (earlier of first anniversary of grant or next annual meeting, subject to continued service).

Key Dates

Recommendation

Keywords

Crinetics Pharmaceuticals, CRNX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership